UPDATE 2-Data from Anacor's nail infection drug disappoints; shares down
* Drug meets main and secondary goals
* Results less impressive than those of competing drug
* Anacor to file for U.S. approval in mid-2013
* Shares down as much as 24 pct (Adds details, analyst comments, updates stock movement)
By Pallavi Ail
Jan 29 (Reuters) - Anacor Pharmaceuticals' experimental drug for treating fungal infection of the nails showed it can cure the disease, but the results fell short of those from a competing drug from Valeant Pharmaceuticals International Inc .
Anacor shares fell 24 percent to $3.95 on the Nasdaq, their lowest in almost one-and-a-half years, before recovering to $4.17, but were still down 19 percent.
Anacor said on Tuesday that 6.5 percent patients treated with its drug tavaborole experienced a complete cure, compared with 0.5 percent of patients on a placebo.
Data released by Valeant in November showed that its drug efinaconazole completely cured 17.8 percent of patients, compared with 3.3 percent of those receiving a placebo. Continued...